Abstract Library

#4631 Correlations between dosimetry and imaging in patients with neuroendocrine tumour treated with 177Lu-DOTATATE

Introduction: Tumour dose may be an important predictor of clinical response, but estimation of a clinically relevant tumour-absorbed dose without high risk of toxicity is challenging.

Conference:

Presenting Author: Gomez Sanchez D

Authors: Gomez Sanchez D, Ribelles M, Fernandez Iglesias A, Paruta Araez L, Mata E,

Keywords: dosimetry, 177Lu-DOTATATE,

#4125 Durvalumab (D) plus Tremelimumab (T) for the treatment of patients with progressive, advanced medullary thyroid carcinoma (MTC) – DUTHY (GETNE-T1812) trial

Introduction: Evidence for immunotherapy (IT) in patients (pts) with MTC is limited and has shown modest activity.

Conference:

Presenting Author:

Authors: García-Álvarez A, Molina-Cerrillo J, Castelo B, Plana M, Iglesias L,

Keywords: Medullary thyroid carcinoma, Immunotherapy, durvalumab, tremelimumab, anti PD-L1, anti CTLA-4,

#3573 Treatment of advanced adrenocortical cancer (ACC): Data from 152 patients of the national and multicenter ICARO_GETHI/SEEN registry

Introduction: Adrenocortical carcinoma (ACC) is a rare tumor with a poor prognosis in stage IV with only one treatment regimen of chemotherapy (CT), etoposide, doxorubicin, and cisplatin (EDP) and mitotane with proven activity in a phase 3 trial.

Conference:

Presenting Author:

Authors: Álvarez-Escolá C, Ballester I, Garcia Donas J, Paja M, Iglesias C,

Keywords: Adrenocortical cancer, mitotane, chemotherapy, survival, registry,

#3258 Ga68-DOTATOC PET/CT clinical impact in patients with neuroendocrine tumors (preliminary results)

Introduction: Ga68-DOTATOC PET/CT enables the detection of cells with overexpression of somatostatin receptors, especially subtypes 2 and 5. This is the basis for its use in the study of neuroendocrine tumors (NETs). Detection of a higher number of lesions is not necessarily followed by a modification of therapeutic approach. From our point of view this is the main success of this technique the impact in the management of these patients.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Suarez-Piñera M, Domenech B, Rivera E, Visa L, Iglesias M,

Keywords: Ga68-DOTATOC PET/CT, clinical management,

#3090 Retrospective Experience with Pherochromocytoma (PH) and Paraganglioma (PG) in a Single Argentinian Institution

Introduction: Pherochromocytoma (PH) and paraganglioma (PG) are neuroendocrine tumors arising in cromaffin cells in the adrenal medulla or extra adrenal paraganglia respectively. Clinical presentation is diverse. All PG/PH have malignant potential. Hereditary cases comprise up to 40% of all PG/PH.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dioca M, Calabretta M, Iglesias L, Rojas Bilbao E, Califano I,

Keywords: Pherochromocytoma and paraganglioma (PG),